Erythropoietin (EPO) Global Market Report 2024

Description

Erythropoietin (EPO) is a glycoprotein hormone naturally produced by the peritubular cells of the kidney, stimulating the production of red blood cells. It is utilized in the treatment of anemia, a condition characterized by a shortage of red blood cells. Symptoms of anemia, such as weakness, fatigue, and shortness of breath, arise due to the crucial role of red blood cells in delivering oxygen to tissues and organs.

The primary types of erythropoietin products include epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. Epoetin alfa is a recombinant DNA-derived human erythropoietin that is synthesized in cell culture. Erythropoietin falls into different drug classes, including biologics and biosimilars, and finds applications in various medical fields such as cancer, hematology, renal diseases, neurology, and others.

The erythropoietin (EPO) market research report is one of a series of new reports from The Business Research Company that provides erythropoietin (EPO) market statistics, including erythropoietin (EPO) industry global market size, regional shares, competitors with an erythropoietin (EPO) market share, detailed erythropoietin (EPO) market segments, market trends and opportunities, and any further data you may need to thrive in the erythropoietin (EPO) industry. This erythropoietin (EPO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The erythropoietin (epo) market size has grown rapidly in recent years. It will grow from $17.29 billion in 2023 to $19.25 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth observed in the historic period can be attributed to several factors, including increased patient education and awareness, consolidation within the pharmaceutical industry, policies related to healthcare reimbursement, expansion of the market coupled with demand growth, and the impact of patent expiration and entry of biosimilar products.

The erythropoietin (epo) market size is expected to see rapid growth in the next few years. It will grow to $30.92 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%. The forecasted growth is driven by market competition, biosimilar impact, disease prevalence projections, healthcare policy changes, emerging markets, and increased focus on clinical trials. Key trends include supply chain management advancements, global expansion, patient education, reimbursement policy evolution, and industry consolidation.

The increasing prevalence of chronic kidney diseases is expected to drive the demand for erythropoietin in the market. The rise in cases of chronic kidney disease necessitates the administration of erythropoietin, which stimulates the production of red blood cells, aiding in immune improvement. A report from the Centers for Disease Control and Prevention in March 2021 revealed that approximately 15% of adults in the United States, equating to 37 million people, were estimated to have chronic kidney disease (CKD). The prevalence is higher among individuals aged 65 or older (38%), followed by those aged 45-64 (13%), and those aged 18-44 (7%). The anemia conditions resulting from chronic kidney diseases contribute to an increased demand for erythropoietin, thereby fostering market growth.

The growth of the erythropoietin market may be hindered by stringent regulations governing the production and sales of erythropoietin drugs. In the European Community (EC), advanced medicinal products, especially those manufactured using biotechnological processes such as recombinant DNA technology, must comply with marketing authorization (MA) regulations outlined in Regulation (EC) No. 726/04 issued by the EC. The regulatory landscape for biosimilars, including erythropoietin, is intricate and primarily governed by guidelines established by the European Medicines Agency (EMEA). Additionally, recombinant human erythropoietin (rHuEPO) must adhere to specific guidelines within its product class, in addition to regulations covering quality, clinical, and non-clinical aspects, as defined by the EMEA.

The anticipated growth of the erythropoietin market is expected to be driven by the increasing incidence of hematologic cancer. Hematologic cancer constitutes a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including diseases such as leukemia, lymphoma, and myeloma. Erythropoietin (EPO) plays a crucial role in managing cancer-related anemia by stimulating the production of red blood cells, thereby alleviating anemia in cancer patients, particularly those undergoing chemotherapy. For instance, in 2023, the American Cancer Society estimates that leukemia is expected to affect 59,610 Americans and cause 23,710 deaths. Additionally, new cases of non-Hodgkin lymphoma are projected to impact 80,550 people in the United States, resulting in 20,180 deaths. Consequently, the increasing prevalence of hematologic cancers is driving the forward momentum of the erythropoietin market.

Major players in the erythropoietin market are introducing innovative products such as Yi Bao (Human Erythropoietin for Injection) to drive business growth, enhance productivity, and explore new markets. Yi Bao is a recombinant human erythropoietin produced using CHO cells. Wanbang Biopharmaceuticals Co. Ltd., a China-based pharmaceutical company, obtained approval from the National Medical Products Administration (NMPA) in September 2021 for Yi Bao's use in treating anemia caused by chemotherapy in patients with non-myeloid malignancies. Yi Bao closely resembles the imported innovator drug, exhibiting precise efficacy and fewer side effects.

Major players in the erythropoietin market are innovating with products such as Varenzin-CA1 to solidify their market position. Varenzin-CA1 (molidustat oral suspension) is a conditionally approved drug by the FDA designed to manage nonregenerative anemia associated with chronic kidney disease (CKD) in cats. Elanco, a US-based pharmaceutical company, secured FDA approval for Varenzin-CA1 in May 2023. This breakthrough innovation for cats boasts a unique mode of action that triggers the genetic transcription of erythropoietin (EPO), leading to increased EPO and red blood cell production in a cat's body. Varenzin-CA1 sets a new standard of care for cats experiencing nonregenerative anemia due to CKD, offering convenience for at-home use.

Major companies operating in the erythropoietin (epo) market report are BASF SE, Hoffmann-La Roche AG, Merck Sharp & Dohme LLC, Sanofi SA, Thermo Fisher Scientific Inc., Associated British Foods PLC, DuPont de Nemours Inc., Kerry Group PLC, Firmenich SA, Koninklijke DSM NV, Dyadic International Inc., Novozymes A/S, Endo International PLC, Chr Hansen Holding A/S, Advanced Enzyme Technologies Ltd., Catalyst Pharmaceuticals Inc., Codexis Inc., AB Enzymes GmbH, Brain Biotech AG, Biocatalysts Ltd., Xike Biotechnology Co. Ltd., Amano Enzyme Inc., Enzyme Development Corporation, Lumis Biotech Pvt. Ltd., Teknisk-Kemiske Laboratorium ApS, Creative Enzymes Co. Ltd., BioResource International Inc., Enzyme Bioscience Pvt. Ltd., Sunson Industry Group Co. Ltd.

North America was the largest region in the erythropoietin (EPO) market in 2023. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in the erythropoietin (epo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the erythropoietin (epo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The erythropoietin market consists of sales of epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin beta. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Erythropoietin (EPO) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on erythropoietin (epo) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for erythropoietin (epo) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The erythropoietin (epo) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Product: Epoetin-alfa; Epoetin-beta; Darbepoetin-alfa; Other Products
2) By Drug Class: Biologist; Biosimilar
3) By Application: Cancer; Hematology; Renal diseases; Neurology; Other Applications
Companies Mentioned: BASF SE; Hoffmann-La Roche AG; Merck Sharp & Dohme LLC; Sanofi SA; Thermo Fisher Scientific Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r15093

1. Executive Summary

2. Erythropoietin (EPO) Market Characteristics

3. Erythropoietin (EPO) Market Trends And Strategies

4. Erythropoietin (EPO) Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Erythropoietin (EPO) Market Size and Growth

5.1. Global Erythropoietin (EPO) Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Erythropoietin (EPO) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Erythropoietin (EPO) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Erythropoietin (EPO) Market Segmentation

6.1. Global Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Other Products
6.2. Global Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Biologis
Biosimilar
6.3. Global Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Cancer
Hematology
Renal diseases
Neurology
Other Applications

7. Erythropoietin (EPO) Market Regional And Country Analysis

7.1. Global Erythropoietin (EPO) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Erythropoietin (EPO) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Erythropoietin (EPO) Market

8.1. Asia-Pacific Erythropoietin (EPO) Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Erythropoietin (EPO) Market

9.1. China Erythropoietin (EPO) Market Overview
9.2. China Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Erythropoietin (EPO) Market

10.1. India Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Erythropoietin (EPO) Market

11.1. Japan Erythropoietin (EPO) Market Overview
11.2. Japan Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Erythropoietin (EPO) Market

12.1. Australia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Erythropoietin (EPO) Market

13.1. Indonesia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Erythropoietin (EPO) Market

14.1. South Korea Erythropoietin (EPO) Market Overview
14.2. South Korea Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Erythropoietin (EPO) Market

15.1. Western Europe Erythropoietin (EPO) Market Overview
15.2. Western Europe Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Erythropoietin (EPO) Market

16.1. UK Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Erythropoietin (EPO) Market

17.1. Germany Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Erythropoietin (EPO) Market

18.1. France Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Erythropoietin (EPO) Market

19.1. Italy Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Erythropoietin (EPO) Market

20.1. Spain Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Erythropoietin (EPO) Market

21.1. Eastern Europe Erythropoietin (EPO) Market Overview
21.2. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Erythropoietin (EPO) Market

22.1. Russia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Erythropoietin (EPO) Market

23.1. North America Erythropoietin (EPO) Market Overview
23.2. North America Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Erythropoietin (EPO) Market

24.1. USA Erythropoietin (EPO) Market Overview
24.2. USA Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Erythropoietin (EPO) Market

25.1. Canada Erythropoietin (EPO) Market Overview
25.2. Canada Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Erythropoietin (EPO) Market

26.1. South America Erythropoietin (EPO) Market Overview
26.2. South America Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Erythropoietin (EPO) Market

27.1. Brazil Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Erythropoietin (EPO) Market

28.1. Middle East Erythropoietin (EPO) Market Overview
28.2. Middle East Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Erythropoietin (EPO) Market

29.1. Africa Erythropoietin (EPO) Market Overview
29.2. Africa Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Erythropoietin (EPO) Market Competitive Landscape And Company Profiles

30.1. Erythropoietin (EPO) Market Competitive Landscape
30.2. Erythropoietin (EPO) Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson & Johnson Services Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. F Hoffmann-La Roche Ltd.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Roche Holding AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis International AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Erythropoietin (EPO) Market Other Major And Innovative Companies

31.1. LG Life Sciences Ltd.
31.2. LG Chem Ltd.
31.3. Amgen Inc.
31.4. Teva Pharmaceutical Industries Ltd.
31.5. Sandoz International GmbH
31.6. Chugai Pharmaceutical Co. Ltd.
31.7. Meiji Seika Pharma Co. Ltd.
31.8. Sun Pharmaceutical Industries Ltd.
31.9. Kyowa Kirin Co. Ltd.
31.10. Dr Reddy's Laboratories Ltd.
31.11. 3SBio Inc.
31.12. Celltrion Inc.
31.13. Watson Pharmaceuticals Inc.
31.14. Biocon Limited
31.15. Emcure Pharmaceuticals Ltd.

32. Global Erythropoietin (EPO) Market Competitive Benchmarking

33. Global Erythropoietin (EPO) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Erythropoietin (EPO) Market

35. Erythropoietin (EPO) Market Future Outlook and Potential Analysis

35.1 Erythropoietin (EPO) Market In 2028 - Countries Offering Most New Opportunities
35.2 Erythropoietin (EPO) Market In 2028 - Segments Offering Most New Opportunities
35.3 Erythropoietin (EPO) Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer